The fully linked HTML version of this article has now been published.
JCS ePress
online publication date 9 Mar 2004
doi: 10.1242/jcs.01028
Research Article
Partitioning of IGFBP-5 actions in myogenesis: IGF-independent anti-apoptotic function
Laura J. Cobb,
Dervis A.M. Salih,
Ivelisse Gonzalez,
Gyanendra Tripathi,
Emma J. Carter,
Fiona Lovett,
Cathy Holding,
and
Jennifer M. Pell*
* Author for correspondence (e-mail: jenny.pell{at}bbsrc.ac.uk)
Igfbp5 is upregulated during the differentiation of several key cell lineages and in some tumours; the function of IGFBP-5 in these physiological and pathological situations is unknown. Since IGFBP-5 contains sequence motifs consistent with IGF-independent actions, the aim of these studies was to distinguish between IGF-dependent and -independent actions of IGFBP-5. Myc-tagged wild-type (termed wtIGFBP-5) and non-IGF binding mouse Igfbp5 (termed mutIGFBP-5) cDNAs were generated and used to transfect C2 myoblasts, a cell line that undergoes differentiation to myotubes in an IGF- and IGFBP-5-regulated manner. WtIGFBP-5, but not mutIGFBP-5, inhibited myogenesis, as assessed by cell morphology, MHC immunocytochemistry and caveolin 3 expression. However, both wt- and mutIGFBP-5 increased cell survival and decreased apoptosis, as indicated by decreased caspase-3 activity and cell surface annexin V binding. Further examination of apoptotic pathways revealed that wt- and mutIGFBP-5 ameliorated the increase in caspase-9 but not the modest increase in caspase-8 during myogenesis, suggesting that IGFBP-5 increased cell survival via inhibition of intrinsic cell death pathways in an IGF-independent manner. The relationship between IGF-II and IGFBP-5 was examined further by cotransfecting C2 myoblasts with antisense Igf2 (previously established to induce increased cell death) and Igfbp5; both wt- and mutIGFBP-5 conferred equivalent protection against the decreased cell survival and increased apoptosis. In conclusion, we have partitioned IGFBP-5 action in myogenesis into IGF-dependent inhibition of differentiation and IGF-independent cell survival. Our findings suggest that, by regulation of cell survival, IGFBP-5 has an autonomous role in the regulation of cell fate in development and in tumourigenesis.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati
Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
E. J. Carter, R. A. Cosgrove, I. Gonzalez, J. H. Eisemann, F. A. Lovett, L. J. Cobb, and J. M. Pell
MEK5 and ERK5 are mediators of the pro-myogenic actions of IGF-2
J. Cell Sci.,
September 1, 2009;
122(17):
3104 - 3112.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Tripathi, D. A. M. Salih, A. C. Drozd, R. A. Cosgrove, L. J. Cobb, and J. M. Pell
IGF-independent effects of insulin-like growth factor binding protein-5 (Igfbp5) in vivo
FASEB J,
August 1, 2009;
23(8):
2616 - 2626.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Yang, K. L. MacQuarrie, E. Analau, A. E. Tyler, F. J. Dilworth, Y. Cao, S. J. Diede, and S. J. Tapscott
MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an arrested myoblast phase to a differentiated state
Genes & Dev.,
March 15, 2009;
23(6):
694 - 707.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Ren, P. Yin, and C. Duan
IGFBP-5 regulates muscle cell differentiation by binding to IGF-II and switching on the IGF-II auto-regulation loop
J. Cell Biol.,
September 8, 2008;
182(5):
979 - 991.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Al-Shanti and C. E Stewart
PD98059 enhances C2 myoblast differentiation through p38 MAPK activation: a novel role for PD98059
J. Endocrinol.,
July 1, 2008;
198(1):
243 - 252.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. R. Dayton and M. E. White
Cellular and molecular regulation of muscle growth and development in meat animals
J Anim Sci,
April 1, 2008;
86(14_suppl):
E217 - E225.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Mukherjee, E. M. Wilson, and P. Rotwein
Insulin-Like Growth Factor (IGF) Binding Protein-5 Blocks Skeletal Muscle Differentiation by Inhibiting IGF Actions
Mol. Endocrinol.,
January 1, 2008;
22(1):
206 - 215.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. S. Kim, Y. B. Seu, S.-H. Baek, M. J. Kim, K. J. Kim, J. H. Kim, and J.-R. Kim
Induction of Cellular Senescence by Insulin-like Growth Factor Binding Protein-5 through a p53-dependent Mechanism
Mol. Biol. Cell,
November 1, 2007;
18(11):
4543 - 4552.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Mazroui, S. Di Marco, R. J. Kaufman, and I.-E. Gallouzi
Inhibition of the Ubiquitin-Proteasome System Induces Stress Granule Formation
Mol. Biol. Cell,
July 1, 2007;
18(7):
2603 - 2618.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A M Solomon and P M G Bouloux
Modifying muscle mass - the endocrine perspective.
J. Endocrinol.,
November 1, 2006;
191(2):
349 - 360.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Zhao, P. Yin, L. A. Bach, and C. Duan
Several Acidic Amino Acids in the N-domain of Insulin-like Growth Factor-binding Protein-5 Are Important for Its Transactivation Activity
J. Biol. Chem.,
May 19, 2006;
281(20):
14184 - 14191.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. H. Lang, B. J. Krawiec, D. Huber, J. M. McCoy, and R. A. Frost
Sepsis and inflammatory insults downregulate IGFBP-5, but not IGFBP-4, in skeletal muscle via a TNF-dependent mechanism
Am J Physiol Regulatory Integrative Comp Physiol,
April 1, 2006;
290(4):
R963 - R972.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Granado, T. Priego, A. I. Martin, M{a} A. Villanua, and A. Lopez-Calderon
Ghrelin receptor agonist GHRP-2 prevents arthritis-induced increase in E3 ubiquitin-ligating enzymes MuRF1 and MAFbx gene expression in skeletal muscle
Am J Physiol Endocrinol Metab,
December 1, 2005;
289(6):
E1007 - E1014.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M S Pampusch, G Xi, E Kamanga-Sollo, K J Loseth, M R Hathaway, W R Dayton, and M E White
Production of recombinant porcine IGF-binding protein-5 and its effect on proliferation of porcine embryonic myoblast cultures in the presence and absence of IGF-I and Long-R3-IGF-I
J. Endocrinol.,
April 1, 2005;
185(1):
197 - 206.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. M. Salih, S. Mohan, Y. Kasukawa, G. Tripathi, F. A. Lovett, N. F. Anderson, E. J. Carter, J. E. Wergedal, D. J. Baylink, and J. M. Pell
Insulin-Like Growth Factor-Binding Protein-5 Induces a Gender-Related Decrease in Bone Mineral Density in Transgenic Mice
Endocrinology,
February 1, 2005;
146(2):
931 - 940.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Yin, Q. Xu, and C. Duan
Paradoxical Actions of Endogenous and Exogenous Insulin-like Growth Factor-binding Protein-5 Revealed by RNA Interference Analysis
J. Biol. Chem.,
July 30, 2004;
279(31):
32660 - 32666.
[Abstract]
[Full Text]
[PDF]
|
 |
|
© The Company of Biologists Ltd 2004